Pharmacoeconomic Analysis of Administration of Famotidine iv Push vs. Intermittent Slow iv Infusion

Annals of Pharmacotherapy

Volumn 31, Issue 5, 1997, Pages 645-

  Ambrose, Paul G ^a   Quintiliani, Richard ^b   Nightingale, Charles H ^c  

^a HARTFORD HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; NURSING; PRIORITY JOURNAL;

FAMOTIDINE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE;

EID: 0030998447     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/106002809703100521     Document Type: Letter

References (4)

1. Product information. Pepcid injection (famotidine). West Point, PA: Merck & Co., Inc., 1993.
2. Ohnishi K. Pharmacokinetics of famotidine after intravenous administration in liver disease. Am J Gastroenterol 1991; 86: 41–5.
3. Lipsy RJ, Freeman CD. Hemodynamic effects of famotidine in critically ill patients. Pharmacotherapy 1995; 15: 48–51.
4. Fish DN. Safety and cost of rapid i.v. injection of famotidine in critically ill patients. Am J Health-Syst Pharm 1995; 52: 1889–94.